Colorectal cancer (CRC) is a disease with high incidence, especially in developed countries. Long non-coding RNAs (lncRNAs) are new research hotspots for their vital roles in regulating gene expression. This study aims to investigate the prognostic value of lncRNAs in CRC patients.
to the revelation of key factors in CRC, such as interleukins [10] and DEAH box polypeptide 32 [11] . However, few studies refered to a wide-range expression profile of long non-coding RNAs (lncRNAs) in CRC. lncRNAs are non-coding RNAs longer than 200 nt, participating in diverse cellular activities as key regulators of gene expression. Some lncRNAs, such as ADAMTS9-AS2, are tumor suppressors [12] , while some may facilitate tumor development and progression, among which MALAT1 and AFAP1-AS1 have been reported as therapeutic targets for cancers [13, 14] . A recent study found that 761 lncRNAs were hypermethylated in CRC tissue samples [15] , further emphasizing the role of lncRNAs in CRC development. Still, more expression profiles and the application value of lncRNAs in CRC need to be investigated.
This study aimed at revealing the role of lncRNAs in the prognosis of CRC. We selected 21 cancer-related lncRNAs that might be involved in cancer development according to existed researches (Supplementary Table) , and detected their expression in CRC tissue samples compared to normal samples by means of PCR array. Seven of these lncRNAs were identified to be up-or down-regulated in CRC. A 120-week-long follow-up was performed on 30 CRC patients to investigate the possible prognostic role of the seven lncRNAs in CRC. These results will provide proof for the application of lncRNAs in CRC prognosis.
Materials and methods
Clinical samples. A total of 15 female and 15 male patients (Table 1 ) diagnosed with CRC were selected from the patients that underwent radical surgical resection during 2010 to 2013. None of the patients had accepted chemotherapy or radiotherapy before the surgery. The cancer tissue and adjacent normal tissue samples were obtained during the surgery. All patients were informed with the experiment before sampling. The tissue samples were frozen in liquid nitrogen immediately after the sampling procedure, and stored at -80°C until RNA extraction. The cancer tissue samples were pathologically examined and staged according to the 7 th version of the American Joint Committee on Cancer (AJCC) cancer staging system. After the surgery, a follow-up of 120 weeks was performed on each patient via reexamination or phone call. This study was approved by a local ethics committee. Three of the 30 patients were randomly selected and their tissue samples were used in PCR array.
RNA extraction and reverse transcription. Total RNAs from tissue samples were extracted with Trizol (Invitrogen, Carlsbad, CA) and purified with PureLink ® RNA Mini Kit (Thermo Scientific, Carlsbad, CA) according to the manufacturers' instructions. The quality and quantity of RNAs were examined by agarose gel electrophoresis and NanoDrop 2000 (Thermo Scientific). First-strand complementary DNAs (cDNAs) were synthesized with RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific).
PCR array. Three of the 30 patients were randomly selected and their tissue samples were used in PCR array after RNA extraction and reverse transcription. The cDNA samples were used for PCR array by TaqMan ® Gene Expression Assays (Applied Biosystems, Carlsbad, CA) with specific primers for 21 lncRNAs according to the manufacturer's instruction. The assay was performed on QuantStudio TM 6 Flex Realtime PCR System (Applied Biosystems). GAPDH was used as an internal control.
qPCR. The expressions of seven up-or down-regulated lncRNAs in each tissue sample of 30 patients were examined on QuantStudio TM 6 Flex Realtime PCR System using the specific primers for these lncRNAs ( 
survival when the follow-up ended were considered as censored data. Survival curves were analyzed by log-rank test or Cox's proportional hazards regression model. PCR array data were analyzed by DataAssist TM Software (Applied Biosystems) using the 2 -ΔΔCt method. Fold change was calculated as the normalized lncRNA expression in the cancer tissue samples divided the normalized expression in the normal tissue samples. In data analysis, P < 0.05 was considered as statistically significant.
Results
Fold changes of lncRNAs in CRC tissue. Based on the PCR array results, the expression levels of 21 lncRNAs in the cancer tissue samples of three patients were compared to their expression in the corresponding adjacent normal tissue after normalized by GAPDH. The heat map showed that HNF1A-AS1, ADAMTS9-AS2, BANCR and TUSC7 might possess of higher levels in normal tissue samples and 14 lncRNAs were relatively up-regulated in cancer tissue samples ( Figure 1 ). It should be noticed that differences among the three patients could be observed, since the expression of some lncRNAs like ACTA2-AS1 and CBR3-AS1 were obviously down-regulated in the adjacent normal tissue sample of patient No. 1 while almost unchanged in patient No. 2 compared to cancer tissue samples.
Data analysis calculated the fold changes of each lncRNA in cancer tissue compared to adjacent normal tissue samples of the three patients (Table 3 ). The expression level change of more than two folds was considered as up-or down-regulated lncRNAs, thus seven of the lncRNAs were filtered out, all of which possessed significant expression changes between cancer and adjacent normal tissue samples (P < 0.05). Among them, AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 and PVT1 were significantly up-regulated, and ADADMTS9-AS2 was significantly down-regulated in cancer tissue samples. The histograms in Figure 2 showed the expression level comparison of the seven lncRNAs more directly. These results implied that the seven lncRNAs found by PCR array might be involved in the progression or development of CRC.
Prognostic potential of seven lncRNAs in CRC. Before the survival curve assay, we performed χ 2 test on the relationship between lncRNA levels and the age, gender, tumor size or TNM stage of the 30 patients, and no obvious association was found (P > 0.05, Table 4 ). When the 30 patients were divided into two groups -15 patients with high AFAP1-AS1 levels and 15 patients with lower AFAP1-AS1 levels -the survival curve assay indicated that the patients with higher AFAP1-AS1 levels had a relatively shorter survival time than patients in the other group (P = 0.0103, Figure 3 and Table 5 ). Similar results were also detected from BCAR4, H19, HOXA-AS2, MALAT1 and PVT1. However, patients with higher ADAMTS9-AS2 levels had a relatively longer survival time (P = 0.0046). Thus lncRNA AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 and PVT1 might be correlated with a worse prognosis and ADAMTS9-AS2 might indicate a better prognosis for CRC patients.
Discussion
As hotspots of gene regulation research, lncRNAs and their pivotal position in cancer modulation have been gradually revealed. This study examined the expression profile of 21 cancer-related lncRNAs in cancer tissue samples of 981 
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CRC patients and screened seven lncRNAs that had significantly aberrant expression between cancer and normal tissue samples. The follow-up and survival curve assay of these seven lncRNAs implied their possible relationship with CRC prognosis.
Among the 21 lncRNAs detected by PCR array, some were up-regulated and some were down-regulated to some extent compared to their expressions in normal tissue samples. In consistent with existed studies of gastric cancer and hepatocellular carcinoma, that HNF1A-AS1 and TUSC7 were down-regulated and acted as tumor suppressors [16, 17] , this study also detected lower expression of the two lncRNAs in CRC samples. In malignant melanoma, BANCR was upregulated and promoted tumor growth [18] , whereas it was inhibited in CRC samples. We conjectured this discrepancy may generate from individual difference or specific regulatory mechanisms of lncRNAs in different cancer cells.
By setting the expression change threshold to 2 folds, we screened seven lncRNAs that had significantly up-or downregulated expression in CRC tissue samples. Among the seven lncRNAs, AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 and PVT1 were up-regulated, while ADAMTS9-AS2 was down-regulated. AFAP1-AS1 has been found hypomethylated in Barrett's esophagus and esophageal adenocarcinoma, which led to its overexpression [19] . BCAR4 has been discovered overexpressing in breast cancer [20] . Overexpression of H19 was found in gastric cancer, breast cancer and bladder cancer, enhancing carcinogenesis and cancer metastasis [21] [22] [23] . Similarly, HOXA-AS2, MALAT1 and PVT1 were all reported to be up-regulated in cancer cells and promoted cancer progression [24] [25] [26] . As for ADAMTS9-AS2, it was revealed to be a cancer suppressor factor that lower expressed in glioma cells, with its overexpression inhibiting glioma cell migration [12] . Together with the findings of this study, it could be deduced that the seven lncRNAs have relatively conserved expression pattern in various cancers including CRC. Their aberrant levels in CRC tissue compared to normal tissue may imply the involvement of these lncRNAs in the development and progression of CRC, which needs to be investigated in further research.
An important finding of this study is the relationship between the seven lncRNAs and the prognosis of CRC. CRC patients with lower AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 or PVT1 levels, or a higher ADAMTS9-AS2 level tended to show better prognosis. Some of these lncRNAs have been investigated in cancers to of possess potential prognostic values. For example, the low ADAMTS9-AS2 expression was a predictor for poor survival in glioma [12] . Poor prognosis in renal cell carcinoma, nasopharyngeal carcinoma, nonsmall-cell lung cancer and cervical cancer has also been found related to high expression of H19 [27] , AFAP1-AS1 [28, 29] and MALAT1 [30] . Similar to the former studies, higher AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 or PVT1 levels and lower ADAMTS9-AS2 level may also predict a poor prognosis of CRC. Existed prognostic markers for CRC included miRNAs, some genome signatures like microsatellite instability and gene copy number, as well as other factors like CD133 [31] [32] [33] [34] . The seven lncRNAs that were up-or down-regulated in CRC tissue sample may have great potential in CRC prognosis. Our future research will concentrate on exploring more accurate prognostic methods for CRC, possibly via combining multiple lncRNAs. Moreover, the detailed functions and regulatory mechanism of these lncRNAs in CRC are worth discussing, which may provide more useful informations for controlling CRC and other cancers.
In summary, this study revealed seven lncRNAs with aberrant expression in CRC tissue samples: AFAP1-AS1, BCAR4, H19, HOXA-AS2, MALAT1 and PVT1 were up-regulated, and ADAMTS9-AS2 was down-regulated. The expression of the seven lncRNAs was associated with the prognosis of CRC patients. These results provided potential prognostic alternatives for the prediction of CRC outcome and the exploration of prognostic strategies.
